Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice

• Published in: Metabolism, clinical and experimental Vol. 111; p. 154324
• Main Authors: Wei, Rui, Cui, Xiaona, Feng, Jin, Gu, Liangbiao, Lang, Shan, Wei, Tianjiao, Yang, Jin, Liu, Junling, Le, Yunyi, Wang, Haining, Yang, Kun, Hong, Tianpei
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2020
• Subjects: Animals; Benzhydryl Compounds - pharmacology; Beta cell regeneration; Blood Glucose - metabolism; C-Peptide - metabolism; Dapagliflozin; Diabetes Mellitus, Experimental - metabolism; Diabetes Mellitus, Type 2 - metabolism; Disease Models, Animal; Endocrine Cells - drug effects; Endocrine Cells - metabolism; Glucagon - metabolism; Glucagon-Like Peptide 1 - metabolism; Glucagon-like peptide-1; Glucagon-Like Peptide-1 Receptor - metabolism; Glucagon-Secreting Cells - drug effects; Glucagon-Secreting Cells - metabolism; Glucose - metabolism; Glucosides - pharmacology; Insulin - metabolism; Insulin-Secreting Cells - metabolism; Male; Mice; Proprotein Convertase 1 - metabolism; Regeneration - drug effects; SGLT2 inhibitor; Sodium-Glucose Transporter 2 Inhibitors; Type 2 diabetes; Type 2 diabetes; Hnf; GLP-1; Dapagliflozin; HFD; DPP-4; Pdx1; SGLT2 inhibitor; CK19; Glucagon-like peptide-1; STZ; SGLT; Ngn3; Beta cell regeneration; OGTT; BrdU
• ISSN: 0026-0495; 1532-8600
• DOI: 10.1016/j.metabol.2020.154324

Clinical trials and animal studies have shown that sodium-glucose co-transporter type 2 (SGLT2) inhibitors improve pancreatic beta cell function. Our study aimed to investigate the effect of dapagliflozin on islet morphology and cell phenotype, and explore the origin and possible reason of the regenerated beta cells. Two diabetic mouse models, db/db mice and pancreatic alpha cell lineage-tracing (glucagon-β-gal) mice whose diabetes was induced by high fat diet combined with streptozotocin, were used. Mice were treated by daily intragastric administration of dapagliflozin (1 mg/kg) or vehicle for 6 weeks. The plasma insulin, glucagon and glucagon-like peptide-1 (GLP-1) were determined by using ELISA. The evaluation of islet morphology and cell phenotype was performed with immunofluorescence. Primary rodent islets and αTC1.9, a mouse alpha cell line, were incubated with dapagliflozin (0.25–25 μmol/L) or vehicle in the presence or absence of GLP-1 receptor antagonist for 24 h in regular or high glucose medium. The expression of specific markers and hormone levels were determined. Treatment with dapagliflozin significantly decreased blood glucose in the two diabetic models and upregulated plasma insulin and GLP-1 levels in db/db mice. The dapagliflozin treatment increased islet and beta cell numbers in the two diabetic mice. The beta cell proliferation as indicated by C-peptide and BrdU double-positive cells was boosted by dapagliflozin. The alpha to beta cell conversion, as evaluated by glucagon and insulin double-positive cells and confirmed by using alpha cell lineage-tracing, was facilitated by dapagliflozin. After the dapagliflozin treatment, some insulin-positive cells were located in the duct compartment or even co-localized with duct cell markers, suggestive of duct-derived beta cell neogenesis. In cultured primary rodent islets and αTC1.9 cells, dapagliflozin upregulated the expression of pancreatic endocrine progenitor and beta cell specific markers (including Pdx1) under high glucose condition. Moreover, dapagliflozin upregulated the expression of Pcsk1 (which encodes prohormone convertase 1/3, an important enzyme for processing proglucagon to GLP-1), and increased GLP-1 content and secretion in αTC1.9 cells. Importantly, the dapagliflozin-induced upregulation of Pdx1 expression was attenuated by GLP-1 receptor antagonist. Except for glucose-lowering effect, dapagliflozin has extra protective effects on beta cells in type 2 diabetes. Dapagliflozin enhances beta cell self-replication, induces alpha to beta cell conversion, and promotes duct-derived beta cell neogenesis. The promoting effects of dapagliflozin on beta cell regeneration may be partially mediated via GLP-1 secreted from alpha cells. [Display omitted] •Dapagliflozin (Dapa) promotes beta cell regeneration in type 2 diabetic mice.•Dapa enhances beta cell self-replication and induces alpha to beta cell conversion.•Dapa promotes duct-derived beta cell neogenesis.•Dapa promotes beta cell regeneration possibly by inducing alpha cell GLP-1 release.